A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis

2008 ◽  
Vol 28 (5) ◽  
pp. 650-658 ◽  
Author(s):  
Jill K. J. Gaidos ◽  
Bruce E. Hillner ◽  
Arun J. Sanyal
Keyword(s):  
Liver Biopsy ◽  
Decision Analysis ◽  
Nonalcoholic Steatohepatitis ◽  
Analysis Study

Liver Histological Improvement After Administration of High-Dose Vitamin C in Guinea Pig with Nonalcoholic Steatohepatitis

2018 ◽  
Vol 88 (5-6) ◽  
pp. 263-269
Author(s):  
Seong-Hoon Park ◽  
A Lum Han ◽  
Na-Hyung Kim ◽  
Sae-Ron Shin
Keyword(s):  
Liver Biopsy ◽  
Vitamin C ◽  
Nonalcoholic Steatohepatitis ◽  
Guinea Pigs ◽  
Normal Diet ◽  
High Dose ◽  
Biochemical Tests ◽  
Deficient Diet ◽  
Histological Improvement ◽  
Vit C

Abstract. Background: Vitamin C is a strong antioxidant, and the health effects of vitamin C megadoses have not been validated despite the apparent health benefits. Therefore, the present study sought to confirm the effects of vitamin C megadoses. Materials and Methods : Four groups of six guinea pigs were used. Each group was fed one of the following diets for three weeks: normal diet, methionine choline-deficient diet, methionine choline-deficient diet + vitamin C megadose (MCD + vit C 2.5 g/kg/day), and methionine-choline deficient diet + ursodeoxycholic acid (MCD + UDCA 30 mg/kg/day). The MCD diet was given to induce nonalcoholic steatohepatitis, and UDCA was used to treat nonalcoholic steatohepatitis. Three weeks after initial diet administration, the results of biochemical tests and liver biopsy were compared between the groups. Results: The cytoplasm state was similar in the MCD + vit C and MCD + UDCA groups, exhibiting clearing of the cytoplasm and ballooning degeneration. However, macrovesicular steatosis was not observed in the MCD + vit C group. Aspartate transaminase and alanine transaminase were elevated significantly following vitamin C administration. Conclusions: The present study confirmed that alone vitamin C megadoses are potential remedies for nonalcoholic steatohepatitis, based on the liver biopsy results of guinea pigs that were unable to synthesize vitamin C.

scholarly journals Nonalcoholic Steatohepatitis: An Evolving Diagnosis

2000 ◽  
Vol 14 (4) ◽  
pp. 321-326 ◽  
Author(s):  
Brent A Neuschwander-Tetri
Keyword(s):  
Alcohol Abuse ◽  
Liver Biopsy ◽  
Nonalcoholic Steatohepatitis ◽  
Aminotransferase Level ◽  
Obese Patients ◽  
Imaging Studies ◽  
Liver Transplants ◽  
Pathophysiological Role ◽  
Alanine Aminotransferase Level

Nonalcoholic steatohepatitis (NASH) is a histological diagnosis applied to a constellation of liver biopsy findings that develop in the absence of alcohol abuse. Steatosis, a mixed cellular inflammatory infiltrate across the lobule, evidence of hepatocyte injury and fibrosis are the findings that can be seen. This entity is often identified during evaluation of elevated aminotransferases after exclusion of viral, metabolic and other causes of liver disease. Obesity is a major risk factor for NASH. The role of diabetes is less certain, although evidence is accumulating that hyperinsulinism may play an important pathophysiological role. Patients sometimes suffer from right upper quadrant abdominal pain and fatigue; examination may reveal centripetal obesity and hepatomegaly. Although patients are often discovered because of persistent aminotransferase elevations, these enzymes can be normal in NASH. When they are elevated, the alanine aminotransferase level is typically significantly greater than the aspartate aminotransferase level. This can be particularly helpful for excluding occult alcohol abuse. Imaging studies identify hepatic steatosis when the amount of fat in the liver is significant; however, imaging does not distinguish benign steatosis from NASH. Ultimately a liver biopsy is needed to diagnose NASH. The biopsy may be useful for establishing prognosis based on the presence or absence of fibrosis and for excluding other unexpected causes of liver enzyme elevations. Weight loss is the mainstay of treatment for obese patients. About 15% to 40% of NASH patients develop fibrosis; how many of these cases progress to cirrhosis is unknown, but about 1% of liver transplants are performed with a pretransplant diagnosis of NASH.

scholarly journals Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals

2017 ◽  
Vol 7 (1) ◽  
pp. 101-106 ◽  
Author(s):  
Sameh M Abdel Monem
Keyword(s):  
Liver Biopsy ◽  
Fatty Liver ◽  
Nonalcoholic Steatohepatitis ◽  
Laboratory Evaluation ◽  
Control Group ◽  
Case Group ◽  
University Hospitals ◽  
Laboratory Findings ◽  
Nonalcoholic Fatty Liver ◽  
Group I

ABSTRACT Aim Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world. A subgroup of NAFLD patients is characterized by injury to the hepatocytes and inflammation in addition to excessive fat (steatohepatitis), the latter condition is nominated nonalcoholic steatohepatitis (NASH). This work aimed to evaluate the role of probiotics on the outcome of NASH in patients admitted to the Tropical Medicine Department, Faculty of Medicine, Zagazig University (inpatients and outpatients). Materials and methods This study was performed on 30 patients (17 males and 13 females), with body mass index from 30 to 35 and average age of 44 years with bright fatty liver in ultrasonography and raised alanine transaminase (ALT) and aspartate transaminase (AST) and positive liver biopsy findings. The patients were divided into group I (case group) that included 15 patients who received probiotics and group II of 15 patients as control group who did not receive probiotics; the study was conducted between November 2014 and April 2016. Clinical assessment, laboratory evaluation, pelvic-abdominal ultrasound, and liver biopsy of all cases were carried out. Results In this study, there was significant decrease in liver enzymes (ALT and AST) and no statistically significant other laboratory findings. Also there was relief for dyspepsia in some patients. Conclusion Probiotics treatment is effective, safe, well-tolerated, inexpensive, appropriate for long-term use, and optimally, works at multiple levels to downregulate inflammatory mediators, and therefore, probiotics could be an option in the treatment of NASH. How to cite this article Monem SMA. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepato-Gastroenterol 2017;7(1):101-106.

scholarly journals Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis

2021 ◽  
Vol 10 (8) ◽  
Author(s):  
Grzegorz Styczynski ◽  
Piotr Kalinowski ◽  
Łukasz Michałowski ◽  
Rafał Paluszkiewicz ◽  
Bogna Ziarkiewicz‐Wróblewska ◽  
...  
Keyword(s):  
Morbid Obesity ◽  
Liver Biopsy ◽  
Right Ventricular ◽  
Nonalcoholic Steatohepatitis ◽  
Left Ventricular ◽  
Interquartile Range ◽  
Additional Risk Factor ◽  
Nonalcoholic Fatty Liver ◽  
Cardiac Morphology ◽  
Hyperdynamic Circulation

Background The patients with nonalcoholic fatty liver disease demonstrate an increased cardiovascular risk. The adverse influence of liver abnormalities on cardiac function are among many postulated mechanisms behind this association. The aim of the study was to evaluate cardiac morphology and function in patients with morbid obesity referred for bariatric surgery with liver biopsy. Methods and Results We evaluated with echocardiography 171 consecutive patients without known cardiac disease (median age 42 [interquartile range, 37–48] years, median body mass index 43.7 [interquartile range, 41.0–47.5], 67% female patients. Based on the liver biopsy results, there were 44 patients with nonalcoholic steatohepatitis (NASH), 69 patients with isolated steatosis, and 58 patients without steatosis. Patients with NASH demonstrated signs of left ventricular concentric remodeling and hyperdynamic circulation, including indexed left ventricular end‐diastolic diameter [cm/m 2 ]: NASH 1.87 [0.22]; isolated steatosis 2.03 [0.33]; without steatosis 2.01 [0.19], P =0.001; relative wall thickness: NASH 0.49±0.05, isolated steatosis 0.47±0.06, without steatosis 0.46±0.06, P =0.011; cardiac index [L/m 2 ]: NASH 3.05±0.54, isolated steatosis 2.80±0.44, without steatosis 2.79±0.50, P =0.013. After adjustment for sex, age, blood pressure, and heart rate, most of the measures of the left ventricular systolic and diastolic function, left atrial size, right ventricular function, and right ventricular size did not differ between groups. Conclusions In a group of patients with extreme obesity, NASH was associated with left ventricular concentric remodeling and hyperdynamic circulation. Increased cardiac output in NASH may represent an additional risk factor for incident cardiovascular events in this population.

scholarly journals Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy

2016 ◽  
Vol 8 (16) ◽  
pp. 673 ◽  
Author(s):  
Maria Nicoline Baandrup Kristiansen ◽  
Sanne Skovgård Veidal ◽  
Kristoffer Tobias Gustav Rigbolt ◽  
Kirstine Sloth Tølbøl ◽  
Jonathan David Roth ◽  
...  
Keyword(s):  
Liver Biopsy ◽  
Mouse Models ◽  
Nonalcoholic Steatohepatitis
Sign in / Sign up

Export Citation Format

Share Document